MAZE (MAZE) reported G&A of $12.41M in Q1 2026.

How has MAZE's G&A changed year-over-year?

MAZE's G&A increased by 58.6% year-over-year, from $7.82M to $12.41M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

MAZE MAZE G&A

G&A at other companies

Septerna, Inc.SEPN

$10.29M+50.0%

ZymeworksZYME

$15.07M-11.3%

Nurix Therapeutics, Inc.NRIX

$14.61M+25.4%

MapLight Therapeutics, Inc. MPLT

$10.82M+188%

Relay Therapeutics, Inc.RLAY

$11.03M-41.2%

Adaptive BiotechnologiesADPT

$20.98M+20.6%

Other financials

Income statement

See full

Revenue$20.0M—

Operating income-$26.6M+25.0%

Net income-$24.2M+26.2%

EPS (diluted)-$0.45+60.9%

Balance sheet

See full

Cash & equivalents$198.8M-32.5%

Total debt$61.2M+137%

Total equity$341.7M+17.0%

Total assets$419.7M+26.1%

Cash flow

See full

Operating cash flow-$39.1M-32.5%

CapEx$93.0K-68.9%

Free cash flow-$39.2M-31.5%

Valuation

See full

Market cap$1.48B—

Enterprise value$1.34B—

P/S7.9×—

Profitability

See full

Operating margin-71.5%—

Net margin-65.4%—

FCF margin-65.1%—

Returns & leverage

See full

Return on equity-38.7%—

Debt / equity0.2×+0.1×

Current ratio17.9×+1.8×

Where this comes from

Reported directly by MAZE in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: MAZE’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about MAZE's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MAZE's G&A?: MAZE (MAZE) reported G&A of $12.41M in Q1 2026.
How has MAZE's G&A changed year-over-year?: MAZE's G&A increased by 58.6% year-over-year, from $7.82M to $12.41M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.